Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-131-MIBG therapy for first-relapse high-risk neuroblastoma
jRCT2041190105Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Jan 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iobenguane in neuroblastoma, sponsored by FUJIFILM Toyama Chemical. Primary endpoint: Dose-limiting toxicity. Started Jan 2020; status: completed.
02
Drugs
Iobenguane
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2041190105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041190105.